Icon Bioscience Submits NDA For Dexycu, a Potential Transformational Drug Therapy for Treating Inflammation Associated with Cataract Surgery

Sunnyvale, CA (April 13, 2017) – Icon Bioscience Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced the submission of a...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news